Miracle Mile Advisors LLC Has $2.33 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Miracle Mile Advisors LLC decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,783 shares of the pharmaceutical company’s stock after selling 33 shares during the quarter. Miracle Mile Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $2,329,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Claro Advisors LLC grew its holdings in Vertex Pharmaceuticals by 26.8% in the 4th quarter. Claro Advisors LLC now owns 3,075 shares of the pharmaceutical company’s stock valued at $1,238,000 after buying an additional 650 shares in the last quarter. Fulcrum Capital LLC grew its stake in shares of Vertex Pharmaceuticals by 0.7% in the fourth quarter. Fulcrum Capital LLC now owns 15,494 shares of the pharmaceutical company’s stock valued at $6,239,000 after acquiring an additional 108 shares in the last quarter. Forza Wealth Management LLC increased its position in Vertex Pharmaceuticals by 5.9% during the fourth quarter. Forza Wealth Management LLC now owns 881 shares of the pharmaceutical company’s stock worth $355,000 after acquiring an additional 49 shares during the period. Cooper Financial Group raised its stake in Vertex Pharmaceuticals by 16.1% in the 4th quarter. Cooper Financial Group now owns 4,682 shares of the pharmaceutical company’s stock worth $1,885,000 after purchasing an additional 651 shares in the last quarter. Finally, Wedmont Private Capital grew its position in shares of Vertex Pharmaceuticals by 11.8% during the 4th quarter. Wedmont Private Capital now owns 3,633 shares of the pharmaceutical company’s stock worth $1,488,000 after purchasing an additional 384 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $413.37 on Tuesday. The company has a market capitalization of $106.45 billion, a P/E ratio of -207.72 and a beta of 0.40. The company has a fifty day moving average price of $447.69 and a 200-day moving average price of $467.53. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.67 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on VRTX. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. StockNews.com downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. Canaccord Genuity Group raised their price target on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Truist Financial reduced their price objective on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. Finally, Royal Bank of Canada boosted their target price on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.